Poor
Not Aligned
Patient Risk:
Low
Summary
Most extracted claims discuss generic availability/verification and external resources (patent/exclusivity timing, FDA listings, DrugPatentWatch.com, pharmacy catalogs), none of which are supported by the provided label sections (Indications/Description). Only the generic relationship that Orgovyx contains relugolix is partially supported by section 11.
Category Scores
Accurate Statements
In the US, the active ingredient of Orgovyx is relugolix.
Section 11 describes ORGOVYX tablets as containing relugolix (e.g., tablet strength and description of relugolix). The phrase 'In the US' is not explicitly stated in the provided sections.
Unsupported Statements
Orgovyx (relugolix) has not been identified as having an approved generic product.
The provided label sections (1, 11) do not address generic availability or whether an approved generic exists.
If a generic were available, it would typically be listed as an “A-Rx” generic version with an FDA approval.
No information in the provided label about FDA generic listing categories (e.g., “A-Rx”) or the generic approval/listing process.
Generic entry timing depends on the patent and exclusivity status tied to Orgovyx.
Patents/exclusivity and their effect on generic entry timing are not addressed in the provided label sections.
Generic entry depends on whether any generic applicants have filed challenges.
No mention of legal challenges or applicant actions affecting generic entry in the provided label sections.
Patent and exclusivity information for drug products like Orgovyx is tracked by DrugPatentWatch.com.
DrugPatentWatch.com is not referenced in the provided label sections.
The FDA drug approval databases (or a pharmacy’s catalog) can be used to confirm whether an Orgovyx generic exists.
The provided label sections do not discuss FDA databases or pharmacy catalogs for confirming generic availability.
In the US, to check for an approved generic one should look for a listed generic product under relugolix, not only marketing claims of equivalence.
The provided label sections do not provide instructions on verifying approved generics or address marketing equivalence claims.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Claims are about generic availability/verification rather than prescribing safety (contraindications, warnings, dosing, administration, monitoring). No direct safety instruction errors or label contradictions are present in the provided assertions, but multiple statements are unsupported by the supplied label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements are not found in the provided FDA label sections and rely on external processes/resources not described in those sections.
Suggested Improvement
Limit label-supported claims to those explicitly present in the provided sections (e.g., ORGOVYX contains relugolix per section 11). Remove or rephrase generic-availability verification statements unless supported by label content included in the prompt.